2. Signaling Pathways
  3. Immunology/Inflammation
  4. Glycoprotein VI
  5. Glycoprotein VI Inhibitor

Glycoprotein VI Inhibitor

Glycoprotein VI Inhibitors (5):

Cat. No. Product Name Effect Purity
  • HY-P99013
    Codrituzumab
    		Inhibitor 99.07%
    Codrituzumab (GC33) is a humanized monoclonal antibody targeting human GPC3 (glypican-3), with high affinity (Kd of 0.673 nM). GPC3 is an oncofetal protein expressed on the cell surface of hepatocellular carcinoma (HCC). Codrituzumab induces antibody-dependent cellular cytotoxicity (ADCC) and inhibits tumor growth.
  • HY-P99644
    ACT017
    		Inhibitor 99.00%
    ACT017 is a Fab fragment of humanized anti-GPVI monoclonal antibody. ACT017 inhibits collagen-induced platelet aggregation. ACT017 has the potential for the research of acute ischemic stroke.
  • HY-P990840
    Anti-GPC3 Antibody (YP7)
    		Inhibitor
    Anti-GPC3 Antibody (YP7) is a kind of mouse IgG1, κ chimeric antibody, targeting to human GPC3. The recommend isotype control of Anti-GPC3 Antibody (YP7): Mouse IgG1 kappa, Isotype Control (HY-P99977).
  • HY-P991448
    MDX-1414
    		Inhibitor
    MDX-1414 is a human IgG1 monoclonal antibody (mAb) targeting GPC3. MDX-1414 has antitumor activity in the HepG2 xenograft model. MDX-1414 can be used in liver cancer research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
  • HY-P991216
    ERY-974
    		Inhibitor
    ERY-974 is a T-cell-engaging bispecific antibody (TCB) targeting GPC3. ERY-974 binds to both GPC3 and the CD3 receptor on T cells simultaneously, activating T cells and prompting them to release perforin and granzyme, triggering apoptosis of tumor cells. ERY-974 is promising for research of solid tumors, such as liver cancer.